Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
277 results found
2025 ∙ Vink, K. Kusters, J. Wallinga, J.
Chrono-optimizing vaccine administration: a systematic review and meta-analysis
Adults Older adults COVID-19 Influenza Hepatitis B Hepatitis A Pneumococcal disease Efficacy/effectiveness Administration
Rating:
Critically low
2025 ∙ Fletcher, M. A. Okasha, O. Baay, M. Syrochkina, M. Hayford, K.
Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022
All age groups Pneumococcal disease Administration Efficacy/effectiveness
Rating:
Critically low
2025 ∙ Akther, A. Laurie, C. Elton-Marshall, T. Ly, V. Sulis, G.
Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review
All age groups Healthcare workers Pneumococcal disease Acceptance
Rating:
Not applicable
2025 ∙ Rahimi, H. K. Jasim, A. A. Rezahosseini, O. Harboe, Z. B.
Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis
Adults Older adults Pneumococcal disease Influenza COVID-19 Efficacy/effectiveness Safety Administration
Rating:
Critically low
2025 ∙ Ngamprasertchai, T. Ruenroengbun, N. Kajeekul, R.
Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Adults Older adults Pneumococcal disease Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Ul Haq, M. Z. Irfan, H. Shah, M. S. U. Sumbal, A. Mughal, S. Ashraf, S. Basaria, A. A. A. Abdullah, Chacho, M. A. Ayalew, B. D.
Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
Newborn Pneumococcal disease Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Waszkiewicz, M. Wnuk, K. Switalski, J. Augustynowicz, A.
Knowledge, attitudes, and beliefs of pharmacists regarding vaccinations against influenza and pneumococci - a systematic review
Healthcare workers Influenza Pneumococcal disease Acceptance
Rating:
Not applicable
2025 ∙ Cho, J. Y. Lee, H. Wannaadisai, W. Vietri, J. Chaiyakunapruk, N.
Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines
Adults Older adults Pneumococcal disease Economic aspects
Rating:
Not applicable
2025 ∙ Hirsch, C. Zorger, A. M. Baumann, M. Park, Y. S. Bröckelmann, P. J. Mellinghoff, S. Monsef, I. Skoetz, N. Kreuzberger, N.
Vaccines for preventing infections in adults with solid tumours
Adults Older adults Pneumococcal disease Haemophilus influenzae type B Meningococcal disease Pertussis Hepatitis B Tetanus Poliomyelitis Diphtheria Influenza Herpes zoster COVID-19 Efficacy/effectiveness Safety
Rating:
High
2025 ∙ SAGE
SAGE Evidence to Recommendation Framework: Reduced-dose (1p+1) schedules
Evidence to recommendation table Pneumococcal disease
Download:
Loading...